IntelliGeneScan (IGS) obtained exclusive rights to develop and commercialize a colon cancer diagnostic test based on a biomarker panel discovered at the California Pacific Medical Center (CPMC). The test is minimally invasive, highly accurate, and less expensive than methods currently used in medical practice, reports CPMC.
CPMC says it chose IGS for its market focus and resource strength. In exchange for the license rights, CPMC received an upfront payment and is eligible to receive milestone fees and royalties on sales of products covered by this agreement. IGS also provided CPMC with funding for a research program to expand upon the clinical tests, which led to the initial discovery. Both CPMC and IGS expect the results of this program will confirm the findings of the first battery of tests and also lead to enhancements in its detection processes.